Read by QxMD icon Read

Prostate pet

Andrea Farolfi, Francesco Ceci, Tiziano Graziani, Alessandro Lambertini, Veronica Cervati, Gian Luca Basilico, Tullio Biraghi, Alberto Briganti, Paolo Castellucci, Stefano Fanti
No abstract text is available yet for this article.
February 23, 2018: Clinical Genitourinary Cancer
Fayez Hanna, Ajay Prakash, Ebony Allan, Alhossain A Khalafallah
A 70-year-old man presented with left loin pain without urinary symptoms. Initial investigations with CT showed enlarged para-aortic, mediastinal lymph nodes, right-side renal mass and enlarged prostate. A prostatic-specific antigen (PSA) was alarmingly high at 4750 μg/L (normal <4.0 μg/L). Further investigations included positron emission tomography (PET); both prostate-specific membrane antigen and 18-fluorodeoxyglucose as well as bone scan and bone marrow examination confirmed dual malignancies with B-cell non-Hodgkin's lymphoma (B-NHL) and wide spread metastatic prostatic adenocarcinoma (PA) to the skull, spine, pelvis, liver and lungs...
March 16, 2018: BMJ Case Reports
Benedikt Thomann, Ilias Sachpazidis, Khodor Koubar, Constantinos Zamboglou, Panayiotis Mavroidis, Rolf Wiehle, Anca-Ligia Grosu, Dimos Baltas
PURPOSE: To evaluate the influence of radioresistance and intrafractional movement on the tumour control probability (TCP) in IMRT prostate treatments using simultaneous integrated boosts to PSMA-PET/CT-delineated GTVs. MATERIALS AND METHODS: 13 patients had PSMA-PET/CT prior to prostatectomy and histopathological examination. Two GTVs were available: GTV-PET and GTV-histo, which is the true cancer volume. Focused IMRT plans delivering 77 Gy in 35 fractions to the prostate and 95 Gy to PTV-PET were produced...
March 13, 2018: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
Marc A Bjurlin, Baris Turkbey, Andrew B Rosenkrantz, Sonia Gaur, Peter L Choyke, Samir S Taneja
Imaging is critically important for the diagnosis, staging, and management of men with high-risk prostate cancer. Conventional imaging modalities, including computed tomography and radionuclide bone scan have been employed for local and metastatic staging, but their performance has generally been poor. Sodium fluoride positron emission tomography is recommended when there is high suspicion for bone metastases despite a negative or indeterminate bone scan. Magnetic resonance imaging has advantages in local staging but its value depends on the extent of disease...
March 12, 2018: Urology
Marc Pretze, Andreas Hien, Matthias Raedle, Ralf Schirrmacher, Carmen Wängler, Björn Wängler
Gold nanoparticles (AuNPs) have widely been used for 70 years in cancer treatment, but only in the last 15 years the focus has been on specific AuNPs with homogeneous size and shape for various areas in science. They constitute a perfect platform for multi-functionalization and therefore enable the enhancement of target affinity. Here we report on the development of tumor specific AuNPs as diagnostic tools intended for the detection of prostate cancer via fluorescence imaging and positron emission tomography (PET)...
March 15, 2018: Bioconjugate Chemistry
Hong Truong, Leonard G Gomella, Mathew L Thakur, Edouard J Trabulsi
PURPOSE: Current approaches to prostate cancer screening and diagnosis are plagued with limitations in diagnostic accuracy. There is a compelling need for biomolecular imaging that will not only detect prostate cancer early but also distinguish prostate cancer from benign lesions accurately. In this topic paper, we review evidence that supports further investigation of VPAC1-targeted PET/CT imaging in the primary diagnosis of prostate cancer. METHODS: A non-systematic review of Medline/PubMed was performed...
March 14, 2018: World Journal of Urology
Kambiz Rahbar, Ali Afshar-Oromieh, Martin Bögemann, Stefan Wagner, Michael Schäfers, Lars Stegger, Matthias Weckesser
PURPOSE: PSMA-targeted PET in patients with prostate cancer (PCa) has a significant impact on treatment decisions. By far the most frequently used PSMA ligand is68 Ga-labelled PSMA-11. However, due to the availability of larger amounts of activity,18 F-labelled PSMA ligands are of major interest. The aim of the present study was to evaluate the biodistribution and performance of the novel18 F-labelled ligand PSMA-1007 at two different time points. METHODS: This retrospective analysis included 40 consecutive patients (mean age 68...
March 14, 2018: European Journal of Nuclear Medicine and Molecular Imaging
Eugene Shenderov, Michael A Gorin, Seohyun Kim, Pamela T Johnson, Mohamad E Allaf, Alan W Partin, Martin G Pomper, Emmanuel S Antonarakis, Kenneth J Pienta, Steven P Rowe
Radiotracers targeting prostate-specific membrane antigen (PSMA), including [18 F]DCFPyL, have been extensively investigated as a means to image prostate cancer more accurately. We present the case of a man with oligometastatic prostate cancer who was also diagnosed with a metastatic small bowel carcinoid tumor following the detection of indeterminate findings on a [18 F]DCFPyL PET and discuss how this case highlights the utility of a newly proposed reporting system for PSMA-targeted PET (PSMA-RADS version 1...
March 2018: Urology Case Reports
Mads Ryø Jochumsen, Michael Alle Madsen, Lise Gammelgaard, Kirsten Bouchelouche
A 75-year-old man with recently diagnosed high-risk prostate cancer was referred for primary staging with Ga-prostate-specific membrane antigen (PSMA) PET/CT. The scan revealed intense Ga-PSMA uptake in a lumbar osteophyte on the right side of level L2/L3, whereas several other spinal osteophytes showed no Ga-PSMA uptake. MRI findings in the L3 vertebra was consistent with a benign Modic type 1 lesion, but MRI showed no signs of malignancy in the osteophyte with high Ga-PMSA uptake. This case presents an osteophyte as an addition to the list of potential benign pitfalls to be aware of when interpreting Ga-PSMA PET/CT...
March 13, 2018: Clinical Nuclear Medicine
Rajender Kumar, Bhagwant Rai Mittal, Anish Bhattacharya, Harmandeep Singh, Shrawan Kumar Singh
The male breast cancer is very less common as compared with the female breast cancer. We report a case of 64-year-old man who presented with the history of lower urinary tract symptoms. The digital rectal examination revealed hard and nodular prostate, and serum prostate-specific antigen level was 23.4 ng/mL. Ga-labeled prostate-specific membrane antigen PET/CT revealed prostate-specific membrane antigen-expressing lesions in the prostate, axillary tail of the right breast, and axillary lymph nodes. Histology from prostate revealed prostate carcinoma, whereas fine-needle aspiration from the breast revealed invasive ductal carcinoma of the breast...
March 13, 2018: Clinical Nuclear Medicine
Christian Filss, Alexander Heinzel, Berthold Miiller, Andreas T J Vogg, Karl-Josef Langen, Felix M Mottaghy
AIM: In metastatic prostate cancer patients PSMA targeting radioligands have gained significant impact as theranostic probes. In this study a correlation between total tumor volume (TTV) and measured kidney dose as well as salivary glands (SG) uptake in177 Lu-PSMA-617 therapy was evaluated. METHODS: Eleven consecutive prostate cancer patients receiving a first cylcle of177 Lu-PSMA-617 (administered activity of approximately 6GBq) were included. The68 Ga-PSMA-11 PET/CT scan previous to therapy was used to determine TTV and SG uptake (glandulae submandibularis) employing PMOD version 3...
February 2018: Nuklearmedizin. Nuclear Medicine
T Steuber, C Jilg, P Tennstedt, A De Bruycker, Derya Tilki, K Decaestecker, T Zilli, B A Jereczek-Fossa, U Wetterauer, A L Grosu, W Schultze-Seemann, H Heinzer, M Graefen, A Morlacco, R J Karnes, Piet Ost
BACKGROUND: Most prostate cancer (PCa) patients with a biochemical failure following primary multimodality treatment (surgery and postoperative radiotherapy) relapse in the nodes. OBJECTIVE: To perform a matched-case analysis in men with lymph node recurrent PCa comparing standard of care (SOC) with metastasis-directed therapy (MDT). DESIGN, SETTING, AND PARTICIPANTS: PCa patients with a prostate-specific antigen (PSA) progression following multimodality treatment were included in this retrospective multi-institutional analysis...
March 10, 2018: European Urology Focus
Sangeeta Taneja, Amarnath Jena, Rajesh Taneja, Aru Singh, Aashim Ahuja
OBJECTIVE: The purpose of this study is to assess whether temporal changes in68 Ga-prostate-specific membrane antigen (PSMA)-HBED-CC uptake and multiparametric MRI parameters derived using PET/MRI can aid in characterization of benign and malignant prostate lesions. MATERIALS AND METHODS: Thirty-five men with 29 malignant and six benign prostate lesions undergoing complete clinical workup including histologic analysis were enrolled for this retrospective study. All had undergone simultaneous whole-body68 Ga-PSMAHBED-CC PET/MRI...
March 12, 2018: AJR. American Journal of Roentgenology
Thomas W Price, George Firth, Charlotte J Eling, Michelle Kinnon, Nicholas J Long, Justin Sturge, Graeme J Stasiuk
A selective fluorescent probe for Zn(ii), AQA-F, has been synthesized. AQA-F exhibits a ratiometric shift in emission of up to 80 nm upon binding Zn(ii) ([AQA-F] = 0.1 mM, [Zn(ii)Cl2 ] = 0-300 μM). An enhancement of quantum yield from Φ = 4.2% to Φ = 35% is also observed. AQA-F has a binding constant, Kd = 15.2 μM with Zn(ii). This probe has been shown to respond to endogenous Zn(ii) levels in vitro in prostate and prostate cancer cell lines. [18F]AQA-F has been synthesized with a radiochemical yield of 8...
March 12, 2018: Chemical Communications: Chem Comm
Vladimir Kepe, Claudio Scafoglio, Jie Liu, William H Yong, Marvin Bergsneider, Sung-Cheng Huang, Jorge R Barrio, Ernest M Wright
A novel glucose transporter, the sodium glucose cotransporter 2 (SGLT2), has been demonstrated to contribute to the demand for glucose by pancreatic and prostate tumors, and its functional activity has been imaged using a SGLT specific PET imaging probe, α-methyl-4-[F-18]fluoro-4-deoxy-D-glucopyaranoside (Me-4FDG). In this study, Me-4FDG PET was extended to evaluate patients with high-grade astrocytic tumors. Me-4FDG PET scans were performed in four patients diagnosed with WHO Grade III or IV astrocytomas and control subjects, and compared with 2-deoxy-2-[F-18]fluoro-D-glucose (2-FDG) PET and magnetic resonance imaging (MRI) of the same subjects...
March 10, 2018: Journal of Neuro-oncology
Masahide Matsuda, Eiichi Ishikawa, Tetsuya Yamamoto, Kentaro Hatano, Akira Joraku, Yuichi Iizumi, Yosuke Masuda, Hiroyuki Nishiyama, Akira Matsumura
Tumor angiogenesis has attracted increasing attention because of its potential as a valuable marker in the differential diagnosis of brain tumors as well as a novel therapeutic target. Prostate-specific membrane antigen (PSMA) is expressed by the neovasculature endothelium of some tumors, with little to no expression by the tumor cells or normal vasculature endothelium. The aim of this study was to investigate the potential of PSMA for the evaluation of the tumor neovasculature of various brain tumors and the possibility of detecting PSMA expression in brain tumors using PET imaging with89 Zr-Df-IAB2M (anti-PSMA minibody)...
March 9, 2018: Journal of Neuro-oncology
Daniele A Pizzuto, Julian Müller, Urs Mühlematter, Niels J Rupp, Antonia Töpfer, Ashkan Mortezavi, Hannes Nagel, Benedikt Kranzbühler, Daniel Eberli, Irene A Burger
PURPOSE: Given the good correlation between PSMA expression and intraglandular tumour aggressiveness based on immunohistochemistry, there is increasing interest in68 Ga-PSMA-11 PET/MRI for staging prostate cancer (PCA). Therefore, accurate knowledge of prostate anatomy as well as normal distribution of PSMA within the prostate gland is becoming essential. The aim of this study was to investigate the physiological intraprostatic distribution of68 Ga-PSMA-11. METHODS: We retrospectively analysed all patients who underwent a staging68 Ga-PSMA-11 PET/MRI scan between June 2016 and January 2018 for high-risk PCA, underwent radical prostatectomy in our institution, and gave written consent for further data analysis...
March 9, 2018: European Journal of Nuclear Medicine and Molecular Imaging
Ephraim E Parent, David M Schuster
Positron emission tomography (PET) is a functional imaging method that can exploit various aspects of tumor biology to enable greater detection of prostate cancer than can be provided by morphologic imaging alone. Anti-1-amino-3-[18 F]-flurocyclobutane-1-carboxylic acid (18 F-fluciclovine) is a non-naturally occurring amino acid PET radiotracer that is recently United States Food and Drug Administration approved for detection of suspected recurrent prostate cancer. The tumor imaging features of this radiotracer mirror the upregulation of transmembrane amino acid transport that occurs in prostate cancer due to increased amino acid metabolism for energy and protein synthesis...
March 9, 2018: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Thomas J W Klein Nulent, Matthijs H Valstar, Bart de Keizer, Stefan M Willems, Laura A Smit, Abrahim Al-Mamgani, Ludwig E Smeele, Robert J J van Es, Remco de Bree, Wouter V Vogel
OBJECTIVES: Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is used for detection and (re)staging of prostate cancer. However, healthy salivary, seromucous, and lacrimal glands also have high PSMA-ligand uptake. This study aimed to describe physiologic PSMA-ligand uptake distribution characteristics in the head and neck to aid in PSMA PET/CT interpretation and to identify possible new clinical applications for PSMA-ligand imaging. STUDY DESIGN: Thirty consecutive patients who underwent PSMA PET/CT for prostate cancer were evaluated...
January 31, 2018: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Francesco Ceci, Paolo Castellucci, Stefano Fanti
As precision medicine evolves, the contribution of molecular imaging to the management of prostate cancer (PCa) patients, especially for Positron Emission Tomography (PET) imaging, is gaining importance. Highly successful approaches to measure the expression of the prostate specific membrane antigen (PSMA) have been introduced recently. PSMA, the glutamate carboxypeptidase II (GCP-II), is a membrane bound metallo-peptidase that is overexpressed in 90-100% of PCa cells. Due to its selective over-expression, PSMA is a reliable tissue marker for prostate cancer and is considered an ideal target for tumor specific imaging and therapy...
March 8, 2018: Quarterly Journal of Nuclear Medicine and Molecular Imaging
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"